North American Nuclear Medicine/Radiopharmaceuticals Market by Type (Diagnostic (SPECT - Technetium, PET- F-18), Therapeutic (Beta Emitters – I-131, Alpha Emitters, Brachytherapy – Y-90)), Application (Oncology, Cardiology) - Forecasts to 2024

北米の核医学/放射性医薬品市場:種類別(診断(SPECT-テクネチウム、PET- F-18)、治療(ベータエミッター-I-131、アルファエミッター、近接照射療法-Y-90))、用途別(腫瘍学、心臓病学)

◆タイトル:North American Nuclear Medicine/Radiopharmaceuticals Market by Type (Diagnostic (SPECT - Technetium, PET- F-18), Therapeutic (Beta Emitters – I-131, Alpha Emitters, Brachytherapy – Y-90)), Application (Oncology, Cardiology) - Forecasts to 2024
◆商品コード:BT 4151
◆調査・発行会社:MarketsandMarkets
◆発行日:2020年1月24日
◆ページ数:156
◆レポート形式:PDF / 英語
◆納品方法:Eメール(受注後24時間以内)
◆調査対象地域:北米
◆産業分野:バイオテクノロジー
◆販売価格オプション(消費税別)
Single User(1名様閲覧)USD5,650 ⇒換算¥598,900見積依頼/購入/質問フォーム
Multi User (Five User)USD6,650 ⇒換算¥704,900見積依頼/購入/質問フォーム
Corporate License (全社内共有可)USD8,150 ⇒換算¥863,900見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※商品の納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。(振込先:三菱東京UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社)
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※ご購入後、レポートに記載の英語表現や単語の意味に関しましては無料でお答えいたします。(但し、対応範囲は弊社で判断)
※弊社H&Iグローバルリサーチ株式会社はMarketsandMarketsの日本における正規販売代理店です。

【レポートの概要】

MarketsandMarkets社は、核医学/放射性医薬品の北米市場規模が2019年22億ドルから2024年27億ドルまで年平均4.1%成長すると予測しています。本調査レポートでは、北米の核医学/放射性医薬品市場を広く調査・分析し、市場概要、種類別(診断核医学、治療核医学)分析、用途別(診断用途、治療用途)分析、地域別分析、競合動向、企業概要などで取りまとめております。
・イントロダクション
・調査手法
・エグゼクティブサマリー
・プレミアムインサイト
・市場概要
・北米の核医学/放射性医薬品市場:種類別(診断核医学、治療核医学)
・北米の核医学/放射性医薬品市場:用途別(診断用途、治療用途)
・北米の核医学/放射性医薬品市場:地域別
・競合動向
・企業概要

“North American nuclear medicine market is projected to grow at a CAGR of 4.1%.”
The North American nuclear medicine market is projected to reach USD 2.7 billion by 2024 from an estimated USD 2.2 billion in 2019, growing at a CAGR of 4.1% during the forecast period. The North American nuclear medicine market has witnessed various advancements in products and their approvals to meet the needs of patients and radiologists worldwide.
Growth in the market can primarily be attributed to factors such as increasing incidence and prevalence of cancer and cardiac ailments and initiatives to lessen the demand-supply gap of Mo-99.

“The Technetium-99m segment to hold the largest share of the SPECT radiopharmaceuticals market in 2019”
Based on type, the SPECT Radiopharmaceuticals market is segmented into Tc-99m, Tl-201, Ga-67, I-123, and other isotopes. In 2019, the Tc-99m segment is expected to hold the largest share of the SPECT radiopharmaceuticals market. The large share of this segment can be attributed to the fact that Tc-99m is the most commonly used diagnostic radioisotope, which is used in around 80–90% of diagnostic scans and around 30 million patient examinations every year.

“The endocrine tumors segment is projected to grow at the highest CAGR during the forecast period”
Based on application, the North American nuclear medicine market is categorized into thyroid indications, bone metastasis, lymphoma, endocrine tumors, and other indications. The endocrine tumors segment is expected to be the fastest-growing application segment in the therapeutic nuclear medicine applications market. The growth in this segment is majorly driven by the increasing use of therapeutic radiopharmaceuticals in the treatment of endocrine tumors.

“The US to witness the highest growth during the forecast period.”
The North American nuclear medicine market is segmented into the US and Canada, based on country. The US is expected to register the highest CAGR during the forecast period. The growth of the market in the US can be attributed to the development of novel technologies for radioisotope production, government funding, and company initiatives in the country

Break of primary participants was as mentioned below:
 By Company Type: Tier I: 55%, Tier II: 25%, Tier III: 20%
 By Designation: C-Level Executives: 35%, Directors: 25%, Others: 40%
 By Region: North America: 20%, Europe: 25%, Asia Pacific : 40%, RoW: 15%
Cardinal Health (US), GE Healthcare (US), and Curium (France) were the leading players in the North American nuclear medicine market.

Research Coverage
This report studies the North American nuclear medicine market based on type, application, procedural volume, and country. The report also studies the different factors (such as drivers, restraints, and opportunities) affecting the market growth. It analyzes the opportunities and challenges in the market and provides details of the competitive landscape for market leaders. Furthermore, the report analyzes micromarkets with respect to their individual growth trends and forecasts the revenue of the market segments with respect to four main regions and respective countries.

Key Benefits of Buying the Report
This report focuses on various levels of analysis—industry trends, market shares of top players, and company profiles, which together form basic views and analyze the competitive landscape, emerging segments of the North American nuclear medicine market, and their drivers, restraints, and opportunities. The report will help both established firms as well as new entrants/smaller firms to gauge the pulse of the North American nuclear medicine and garner greater market shares.

【レポートの目次】

1 Introduction (Page No. – 20)
1.1 Objectives of the Study
1.2 Market Definition
1.2.1 Market Scope
1.2.2 Markets Covered
1.2.3 Years Considered for the Study
1.3 Currency
1.4 Limitations
1.5 Stakeholders
2 Research Methodology (Page No. – 24)
2.1 Research Data
2.2 Research Methodology Steps
2.2.1 Secondary Data
2.2.1.1 Secondary Sources
2.2.2 Primary Data
2.2.3 Primary Sources
2.2.4 Key Insights From Primary Sources
2.2.5 Market Size Estimation Methodology
2.2.6 Revenue Mapping-Based Market Estimation
2.2.7 Market Data Estimation and Triangulation
2.2.8 Assumptions of the Study
3 Executive Summary (Page No. – 34)
4 Premium Insights (Page No. – 37)
4.1 North American Nuclear Medicine Market Overview
4.2 Market, By Type, (2019)
4.3 North American Diagnostic Nuclear Medicine Procedures Market, By Type, 2019–2024
4.4 North American Therapeutic Procedures Market, By Type (2019–2024)
5 Market Overview (Page No. – 40)
5.1 Introduction
5.1.1 Market Dynamics
5.1.2 Drivers
5.1.2.1 Increasing Incidence and Prevalence of Target Conditions
5.1.2.2 Alpha Radioimmunotherapy-Based Targeted Cancer Treatment
5.1.2.3 Initiatives to Lessen the Demand-Supply Gap of Mo-99
5.1.3 Restraints
5.1.3.1 Short Half-Life of Radiopharmaceuticals
5.1.4 Opportunities
5.1.4.1 Use of Radiopharmaceuticals in Neurological Applications
6 North American Nuclear Medicine/ Radiopharmaceuticals Market: Pipeline Assessment (Page No. – 43)
6.1 Introduction
6.2 Diagnostic Radioisotopes
6.3 Therapeutic Radioisotopes
7 North American Nuclear Medicine/ Radiopharmaceuticals Market, By Type (Page No. – 49)
7.1 Introduction
7.2 Diagnostic Nuclear Medicine
7.2.1 SPECT Radiopharmaceuticals
7.2.1.1 TC-99m
7.2.1.2 TL-201
7.2.1.3 GA-67
7.2.1.4 I-123
7.2.1.5 Other SPECT Isotopes
7.2.2 Pet Radiopharmaceuticals
7.2.2.1 F-18
7.2.2.2 RU-82
7.2.2.3 Other Pet Isotopes
7.3 Therapeutic Nuclear Medicine
7.3.1 Alpha Emitters
7.3.1.1 RA-223
7.3.2 Beta Emitters
7.3.2.1 Iodine-131
7.3.2.2 Y-90
7.3.2.3 SM-153
7.3.2.4 LU-177
7.3.2.5 RH-186
7.3.2.6 Other Beta Emitters
7.3.3 Brachytherapy Isotopes
7.3.3.1 Iodine-125
7.3.3.2 Iridium-192
7.3.3.3 Palladium-103
7.3.3.4 Cesium-131
7.3.3.5 Other Brachytherapy Isotopes
8 North American Nuclear Medicine/Radiopharmaceuticals Market, By Application (Page No. – 69)
8.1 Introduction
8.2 Diagnostic Applications
8.2.1 SPECT Applications
8.2.1.1 Cardiology
8.2.1.1.1 Rising Incidence of CVD has Increased Demand for Cardiac Diagnostic Scans
8.2.1.2 Bone Scans
8.2.1.2.1 Precision of SPECT in Bone Scanning has Driven Dependence on the Technology
8.2.1.3 Thyroid Applications
8.2.1.3.1 Introduction of Dual SPECT/CT Imaging is an Important Trend in the Thyroid Applications Segment
8.2.1.4 Pulmonary Scans
8.2.1.4.1 SPECT/CT has Shown High Accuracy and Sensitivity in Pulmonary Embolism Applications
8.2.1.5 Other SPECT Applications
8.2.2 PET Applications
8.2.2.1 Oncology
8.2.2.1.1 Increasing Cancer Incidence Will Fuel Market Growth
8.2.2.2 Cardiology
8.2.2.2.1 Growing Preference for FDG in Cardiac Imaging is Likely to Boost Market Growth
8.2.2.3 Neurology
8.2.2.3.1 R&D Into Alzheimer’s Disease has Positively Affected Demand for Nuclear Medicine
8.2.2.4 Other PET Applications
8.3 Therapeutic Applications
8.3.1 Thyroid Indications
8.3.1.1 Increasing Prevalence of Thyroid Disorders Will Fuel Market Growth
8.3.2 Bone Metastasis
8.3.2.1 Introduction of Novel Therapies for Bone Metastasis Will Positively Impact the Market
8.3.3 Lymphoma
8.3.3.1 Development of New Isotopes for the Treatment of Lymphoma Presents Huge Growth Opportunities
8.3.4 Endocrine Tumors
8.3.4.1 US Dominates the Therapeutic Nuclear Medicine Market for Endocrine Tumor Applications
8.3.5 Other Indications
9 North American Nuclear Medicine/Radiopharmaceuticals Market: Procedural Volume Assessment (Page No. – 81)
9.1 Introduction
9.2 Diagnostic Procedures
9.2.1 SPECT Procedures
9.2.2 PET Procedures
9.3 Therapeutic Procedures
9.3.1 Beta Emitter Procedures
9.3.2 Alpha Emitter Procedures
9.3.3 Brachytherapy Procedures
10 North American Nuclear Medicine/Radiopharmaceuticals Market, By Country (Page No. – 86)
10.1 Introduction
10.1.1 US
10.1.1.1 The US Holds the Largest Share of the North American Market
10.1.2 Canada
10.1.2.1 Investments to Secure Medical Isotope Supply are Likely to Boost Market Growth

11 Competitive Landscape (Page No. – 100)
11.1 Overview
11.2 Competitive Leadership Mapping
11.2.1 Visionary Leaders
11.2.2 Innovators
11.2.3 Dynamic Differentiators
11.2.4 Emerging Companies
11.3 Competitive Scenario
11.3.1 Product Launches & Approvals
11.3.2 Expansions
11.3.3 Acquisitions
11.3.4 Agreements,Partnerships, & Collaborations
12 Company Profile (Page No. – 106)
(Business Overview, Products Offered, Recent Developments, MnM View)*
12.1 Cardinal Health
12.2 GE Healthcare
12.3 Curium
12.4 Lantheus Medical Imaging, Inc.
12.5 Bayer AG
12.6 Bracco Imaging S.P.A.
12.7 Eczacibaþi-Monrol Nuclear Products
12.8 Nordion, Inc. (A Subsidiary of Sterigenics International)
12.9 Advanced Accelerator Applications (AAA) (A Part of Novartis)
12.10 NTP Radioisotopes Soc, LTD. (A Subsidiary of South African Nuclear Energy Corporation)
12.11 Joint Stock Company Isotope (JSC Isotope)
12.12 Northstar Medical Radioisotopes, LLC
12.13 Eckert & Ziegler
12.14 Jubilant Draximage, Inc. (A Subsidiary of Jubilant Pharma)
12.15 Pharmalogic
12.16 Institute of Isotopes Co., LTD.
12.17 Sinotau Pharmaceuticals Group
12.18 Isotopia Molecular Imaging Limited
12.19 Shine Medical Technologies
12.20 Global Medical Solutions, LTD.
12.21 FDA Approved Radiopharmaceuicals
*Business Overview, Products Offered, Recent Developments, MnM View Might Not Be Captured in Case of Unlisted Companies.
13 Appendix (Page No. – 150)
13.1 Discussion Guide
13.2 Knowledge Store: Marketsandmarkets’ Subscription Portal
13.3 Available Customizations
13.4 Related Reports
13.5 Author Details

List of Tables (96 Tables)
Table 1 New Reactors Expected to Open During the Forecast Period
Table 2 North American Nuclear Medicine Market, By Type, 2017–2024 (USD Million)
Table 3 North American Diagnostic Nuclear Medicine Market, By Type, 2017–2024 (USD Million)
Table 4 North American Diagnostic Nuclear Medicine Market, By Country 2017–2024 (USD Million)
Table 5 Table 1.2. Alternatives to Common TC-99m-Based Diagnostic Procedures in the Setting of Severe TC-99m Shortages
Table 6 North American SPECT Radiopharmaceuticals Market, By Type, 2017–2024 (USD Million)
Table 7 North American SPECT Radiopharmaceuticals Market, By Country, 2017–2024 (USD Million)
Table 8 North American TC-99m Market, By Country, 2017–2024 (USD Million)
Table 9 North American Ti-201 Market, By Country, 2017–2024 (USD Million)
Table 10 North American GA-67 Market, By Country, 2017–2024 (USD Million)
Table 11 North American I-123 Market, By Country, 2017–2024 (USD Million)
Table 12 North American Other SPECT Isotopes Market, By Country, 2017–2024 (USD Million)
Table 13 North American PET Radiopharmaceuticals Market, By Type, 2017–2024 (USD Million)
Table 14 North American PET Radiopharmaceuticals Market, By Country, 2017–2024 (USD Million)
Table 15 North American F-18 Market, By Region, 2017–2024 (USD Million)
Table 16 North American RU-82 Market, By Country, 2017–2024 (USD Million)
Table 17 North American Other PET Isotopes Market, By Country, 2017–2024 (USD Million)
Table 18 North American Therapeutic Nuclear Medicine Market, By Type, 2017–2024 (USD Million)
Table 19 North American Therapeutic Nuclear Medicine Market, By Country, 2017–2024 (USD Million)
Table 20 North American RA-223 Market, By Country, 2017–2024 (USD Million)
Table 21 North American Beta Emitters Market, By Type, 2017–2024 (USD Million)
Table 22 North American Beta Emitters Market, By Country, 2017–2024 (USD Million)
Table 23 North American Iodine-131 Market, By Country, 2017–2024 (USD Million)
Table 24 North American Y-90 Market, By Country, 2017–2024 (USD Million)
Table 25 North American SM-153 Market, By Country, 2017–2024 (USD Million)
Table 26 North American LU-177 Market, By Country, 2017–2024 (USD Million)
Table 27 North American Re-186 Market, By Country, 2017–2024 (USD Million)
Table 28 North American Other Beta Emitters Market, By Country, 2017–2024 (USD Million)
Table 29 North American Brachytherapy Isotopes Market, By Type, 2017–2024 (USD Million)
Table 30 North American Brachytherapy Isotopes Market, By Country, 2017–2024 (USD Million)
Table 31 North American I-125 Market, By Country, 2017–2024 (USD Million)
Table 32 North American Iridium-192 Market, By Country, 2017–2024 (USD Million)
Table 33 North American Palladium-103 Market, By Country, 2017–2024 (USD Million)
Table 34 North American Cesium-131 Market, By Country, 2017–2024 (USD Million)
Table 35 North American Other Brachytherapy Isotopes Market, By Country, 2017–2024 (USD Million)
Table 36 North American SPECT Applications Market, By Type, 2017–2024 (USD Million)
Table 37 North American SPECT Cardiology Applications Market, By Country, 2017–2024 (USD Million)
Table 38 North American SPECT Bone Scans Market, By Country, 2017–2024 (USD Million)
Table 39 North American SPECT Thyroid Applications Market, By Country, 2017–2024 (USD Million)
Table 40 North American SPECT Pulmonary Scans Market, By Country, 2017–2024 (USD Million)
Table 41 North American Other SPECT Applications Market, By Country, 2017–2024 (USD Million)
Table 42 North American PET Applications Market, By Type, 2017–2024 (USD Million)
Table 43 North American PET Oncology Applications Market, By Country, 2017–2024 (USD Million)
Table 44 North American PET Cardiology Applications Market, By Country, 2017–2024 (USD Million)
Table 45 North American PET Neurology Applications Market, By Country, 2017–2024 (USD Million)
Table 46 North American Other PET Applications Market, By Country, 2017–2024 (USD Million)
Table 47 North American Therapeutic Nuclear Medicine Applications Market, By Indication, 2017–2024 (USD Million)
Table 48 North American Therapeutic Nuclear Medicine Market for Thyroid Indications, By Country, 2017–2024 (USD Million)
Table 49 North American Therapeutic Nuclear Medicine Market for Bone Metastasis, By Country, 2017–2024 (USD Million)
Table 50 North American Therapeutic Nuclear Medicine Market for Lymphoma, By Country, 2017–2024 (USD Million)
Table 51 North American Therapeutic Nuclear Medicine Market for Endocrine Tumors, By Country, 2017–2024 (USD Million)
Table 52 North American Therapeutic Nuclear Medicine Market for Other Indications, By Country, 2017–2024 (USD Million)
Table 53 North American Nuclear Medicine Market, By Procedure, 2019–2024 (Thousand Procedures)
Table 54 North American Diagnostic Nuclear Medicine Procedures Market, By Type, 2019–2024 (Thousand Procedures)
Table 55 North American SPECT Procedures Market, By Type, 2019–2024 (Thousand Procedures)
Table 56 North American PET Procedures Market, By Type, 2019–2024 (Thousand Procedures)
Table 57 North American Therapeutic Procedures Market, By Type, 2019–2024 (Thousand Procedures)
Table 58 North American Beta Emitter Procedures Market, By Type, 2019–2024 (Thousand Procedures)
Table 59 North American Alpha Emitter Procedures Market, By Type, 2019–2024 (Thousand Procedures)
Table 60 North American Brachytherapy Procedures Market, By Type, 2019–2024 (Thousand Procedures)
Table 61 North American Nuclear Medicine Market, By Country, 2017–2024 (USD Million)
Table 62 North American Nuclear Medicine Market, By Type, 2017–2024 (USD Million)
Table 63 North American Diagnostic Nuclear Medicine Market, By Type, 2017–2024 (USD Million)
Table 64 North American SPECT Radiopharmaceuticals Market, By Type, 2017–2024 (USD Million)
Table 65 North American SPECT Applications Market, By Type, 2017–2024 (USD Million)
Table 66 North American PET Radiopharmaceuticals Market, By Type, 2017–2024 (USD Million)
Table 67 North American PET Applications Market, By Type, 2017–2024 (USD Million)
Table 68 North American Therapeutic Nuclear Medicine Market, By Type, 2017–2024 (USD Million)
Table 69 North American Beta Emitters Market, By Type, 2017–2024 (USD Million)
Table 70 North American Brachytherapy Isotopes Market, By Type, 2017–2024 (USD Million)
Table 71 North American Therapeutic Nuclear Medicine Applications Market, By Indication, 2017–2024 (USD Million)
Table 72 US: Nuclear Medicine Market, By Type, 2017–2024 (USD Million)
Table 73 US: Diagnostic Nuclear Medicine Market, By Type, 2017–2024 (USD Million)
Table 74 US: SPECT Radiopharmaceuticals Market, By Type, 2017–2024 (USD Million)
Table 75 US: SPECT Applications Market, By Type, 2017–2024 (USD Million)
Table 76 US: PET Radiopharmaceuticals Market, By Type, 2017–2024 (USD Million)
Table 77 US: PET Applications Market, By Type, 2017–2024 (USD Million)
Table 78 US: Therapeutic Nuclear Medicine Market, By Type, 2017–2024 (USD Million)
Table 79 US: Beta Emitters Market, By Type, 2017–2024 (USD Million)
Table 80 US: Brachytherapy Isotopes Market, By Type, 2017–2024 (USD Million)
Table 81 US: Therapeutic Nuclear Medicine Applications Market, By Indication, 2017–2024 (USD Million)
Table 82 Canada: Nuclear Medicine Market, By Type, 2017–2024 (USD Million)
Table 83 Canada: Diagnostic Nuclear Medicine Market, By Type, 2017–2024 (USD Million)
Table 84 Canada: SPECT Radiopharmaceuticals Market, By Type, 2017–2024 (USD Million)
Table 85 Canada: SPECT Applications Market, By Type, 2017–2024 (USD Million)
Table 86 Canada: PET Radiopharmaceuticals Market, By Type, 2017–2024 (USD Million)
Table 87 Canada: PET Applications Market, By Type, 2017–2024 (USD Million)
Table 88 Canada: Therapeutic Nuclear Medicine Market, By Type, 2017–2024 (USD Million)
Table 89 Canada: Beta Emitters Market, By Type, 2017–2024 (USD Million)
Table 90 Canada: Brachytherapy Isotopes Market, By Type, 2017–2024 (USD Million)
Table 91 Canada: Therapeutic Nuclear Medicine Applications Market, By Indication, 2017–2024 (USD Million)
Table 92 Product Launches & Approvals (2017–2019)
Table 93 Expansions (2017–2019)
Table 94 Acquisitions (2017–2019)
Table 95 Agreements, Partnerships, & Collaborations (2017–2019)
Table 96 FDA Approved Radiopharmaceuicals

List of Figures (30 Figures)
Figure 1 Research Methodology: North American Nuclear Medicine Market
Figure 2 Research Design
Figure 3 Breakdown of Primary Interviews: By Company Type, Designation, and Region
Figure 4 Research Methodology: Hypothesis Building
Figure 5 Data Triangulation Methodology
Figure 6 North American Nuclear Medicine Market, By Type, 2019 vs 2024 (USD Million)
Figure 7 North American SPECT Applications Market, By Type, 2019 vs 2024 (USD Million)
Figure 8 North American PET Applications Market, By Type, 2019 vs 2024 (USD Million)
Figure 9 North American Therapeutic Nuclear Medicine Applications Market, By Indication, 2019 vs 2024 (USD Million)
Figure 10 High Prevalence of Cancer to Drive the Market During the Forecast Period
Figure 11 The US Accounted for the Largest Share of the North American Nuclear Medicine Market
Figure 12 SPECT Procedures Segment to Account for the Largest Share of the Market
Figure 13 Alpha Emitters to Account for the Largest Share of the North American Therapeutic Procedures Market
Figure 14 Drivers, Restraints, and Opportunities
Figure 15 Clinical Trials for Diagnostic & Therapeutic Radioisotopes, By Phase, 2011–2025
Figure 16 Clinical Trials for Radioisotopes, By Type, 2011–2025
Figure 17 Clinical Trials for Diagnostic Radioisotopes, By Subtype, 2011–2025
Figure 18 Clinical Trials for Diagnostic Radioisotopes, By Application, 2011–2025
Figure 19 Clinical Trials for Diagnostic Radioisotopes, By Phase, 2011–2025
Figure 20 Clinical Trials for Therapeutic Radioisotopes, By Subtype, 2011–2025
Figure 21 Clinical Trials for Therapeutic Radioisotopes, By Indication, 2011–2025
Figure 22 Clinical Trials for Therapeutic Radioisotopes, By Phase, 2011–2025
Figure 23 North American Nuclear Medicine Market Snapshot
Figure 24 Key Developments in the North American Nuclear Medicine Market, 2017–2019
Figure 25 North American Nuclear Medicine Market: Competitive Leadership Mapping (2018)
Figure 26 Cardinal Health: Company Snapshot (2018)
Figure 27 GE Healthcare: Company Snapshot (2018)
Figure 28 Lantheus Medical Imaging, Inc.: Company Snapshot (2018)
Figure 29 Bayer AG: Company Snapshot (2018)
Figure 30 Eckert & Ziegler: Company Snapshot (2018)

★調査レポート[北米の核医学/放射性医薬品市場:種類別(診断(SPECT-テクネチウム、PET- F-18)、治療(ベータエミッター-I-131、アルファエミッター、近接照射療法-Y-90))、用途別(腫瘍学、心臓病学)] ( North American Nuclear Medicine/Radiopharmaceuticals Market by Type (Diagnostic (SPECT - Technetium, PET- F-18), Therapeutic (Beta Emitters – I-131, Alpha Emitters, Brachytherapy – Y-90)), Application (Oncology, Cardiology) - Forecasts to 2024 / BT 4151) 販売に関する免責事項
[北米の核医学/放射性医薬品市場:種類別(診断(SPECT-テクネチウム、PET- F-18)、治療(ベータエミッター-I-131、アルファエミッター、近接照射療法-Y-90))、用途別(腫瘍学、心臓病学)] ( North American Nuclear Medicine/Radiopharmaceuticals Market by Type (Diagnostic (SPECT - Technetium, PET- F-18), Therapeutic (Beta Emitters – I-131, Alpha Emitters, Brachytherapy – Y-90)), Application (Oncology, Cardiology) - Forecasts to 2024 / BT 4151) についてEメールでお問い合わせ


◆H&Iグローバルリサーチ株式会社のお客様(例)◆